Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey

Unmet needs remain in later lines chronic myeloid leukemia (CML): the response rate and the overall survival of resistant patients in the chronic phase who changed a second-generation TKI in the second line with another TKI with similar action are usually poor, while the off-target toxicities and the potential development of mutations increase. The recent approval of asciminib, a STAMP inhibitor, in the third line, has the potential to soon change the therapeutic algorithm for this subset of patients. Here, we report the results of a GIMEMA survey assessing the number of patients currently treated in the third line in Italy, the current approach in later lines by Italian physicians, and the future role of this drug according to the reason to switch to asciminib (resistance and/or intolerance), as well as the perceptions about the future position of this agent.

Automated summary

Unmet needs exist in later lines of chronic myeloid leukemia (CML) treatment due to poor response and overall survival in resistant patients who switch to a second-generation TKI with similar action in the second line, as well as the increase in off-target toxicities and potential mutations. However, the recent approval of asciminib, a STAMP inhibitor, in the third line could change the treatment algorithm for this patient subset. A GIMEMA survey in Italy evaluated the current number of patients receiving third-line treatment, the current approach in later lines by Italian physicians, and the perceptions about the future role of asciminib.